Integral Diagnostics Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Integral Diagnostics han disminuido a una tasa media anual de -24.6%, mientras que en la industria Healthcare los beneficios crecieron en un 1.5% anualmente. Los ingresos han ido creciendo a una tasa media de 14.9% al año.

Información clave

-24.6%

Tasa de crecimiento de los beneficios

-28.4%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare	2.4%
Tasa de crecimiento de los ingresos	14.9%
Rentabilidad financiera	-19.3%
Margen neto	-12.7%
Próxima actualización de resultados	27 Aug 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos

Cómo gana y gasta dinero Integral Diagnostics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

CHIA:IDX Ingresos, gastos y beneficios (AUD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Dec 23	456	-58	26
30 Sep 23	449	-16	26
30 Jun 23	441	25	25
31 Mar 23	418	23	24
31 Dec 22	395	21	22
30 Sep 22	378	18	21
30 Jun 22	361	15	21
31 Mar 22	361	18	21
31 Dec 21	360	22	22
30 Sep 21	356	26	22
30 Jun 21	351	31	22
31 Mar 21	333	32	21
31 Dec 20	315	32	19
30 Sep 20	295	28	18
30 Jun 20	276	23	16
31 Mar 20	263	22	18
31 Dec 19	250	21	19
30 Sep 19	241	21	21
30 Jun 19	232	21	24
31 Mar 19	222	19	23
31 Dec 18	211	17	23
30 Sep 18	200	16	22
30 Jun 18	189	15	21
31 Mar 18	187	15	21
31 Dec 17	185	15	20
30 Sep 17	182	15	20
30 Jun 17	180	15	20
31 Mar 17	177	16	19
31 Dec 16	175	16	19
30 Sep 16	171	14	18
30 Jun 16	168	11	18
31 Mar 16	165	11	17
31 Dec 15	162	11	17
30 Sep 15	157	8	17
30 Jun 15	151	5	16
30 Jun 14	4	3	1
30 Jun 13	3	3	0

Ingresos de calidad: IDX actualmente no es rentable.

Margen de beneficios creciente: IDX actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: IDX no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 24.6% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de IDX en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: IDX no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Healthcare (-19.1%).

Rentabilidad financiera

Alta ROE: IDX tiene una rentabilidad financiera negativa (-19.26%), ya que actualmente no es rentable.

Integral Diagnostics Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

First half 2024 earnings released: AU$0.29 loss per share (vs AU$0.069 profit in 1H 2023)

Full year 2023 earnings released: EPS: AU$0.11 (vs AU$0.07 in FY 2022)

First half 2023 earnings released: EPS: AU$0.069 (vs AU$0.051 in 1H 2022)

Integral Diagnostics Limited to Report First Half, 2023 Results on Feb 17, 2023

Integral Diagnostics Limited to Report Fiscal Year 2023 Results on Aug 28, 2023

Full year 2022 earnings released

Recent updates

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.

First half dividend of AU$0.025 announced

First half 2024 earnings released: AU$0.29 loss per share (vs AU$0.069 profit in 1H 2023)

IDX™ Announces Appointment of Scott Paterson as Worldwide CFO

Integral Diagnostics Limited, Annual General Meeting, Nov 01, 2024

Integral Diagnostics Limited Announces Change of Company Secretary

Independent Non-Executive Director recently bought AU$258k worth of stock

Integral Diagnostics Limited Announces Resignation of Helen Kurincic as Director Effective 29 November 2023

Investor sentiment deteriorates as stock falls 27%

Integral Diagnostics Limited Appoints Toby Hall as Director

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Six Months Ended June 30, 2023, Payable on October 04, 2023

Full year 2023 earnings released: EPS: AU$0.11 (vs AU$0.07 in FY 2022)

Integral Diagnostics Limited Declares Fully Franked Final Dividend, Payable on October 04, 2023

Integral Diagnostics Limited Announces Board Changes

Upcoming dividend of AU$0.025 per share at 2.0% yield

First half 2023 earnings released: EPS: AU$0.069 (vs AU$0.051 in 1H 2022)

Integral Diagnostics Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2022, Payable on April 4, 2023

Now 21% undervalued

Integral Diagnostics Limited to Report First Half, 2023 Results on Feb 17, 2023

Integral Diagnostics Limited to Report Fiscal Year 2023 Results on Aug 28, 2023

Independent Non-Executive Director recently bought AU$114k worth of stock

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Year Ended June 30, 2022, Payable on October 5, 2022

Full year 2022 earnings released

Investor sentiment improved over the past week

Integral Diagnostics Limited Announces Appointment of Andrew Fay as an Independent Non-Executive Director

Now 21% undervalued after recent price drop

Healius Reportedly Keeps Watching Brief on Integral Diagnostics

Integral Diagnostics Limited (ASX:IDX) ) agreed to acquire Exact Radiology Pty Ltd for NZD 33.3 million.

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Exact Radiology Pty Ltd for approximately AUD 39 million.

Executive Director recently bought AU$70k worth of stock

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

Integral Diagnostics Limited Announces the Distribution for the Six Months Ended December 31, 2021, Payable on April 4, 2022

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS AU$0.16 (vs AU$0.12 in FY 2020)

Executive Director has left the company

First half 2021 earnings released: EPS AU$0.10 (vs AU$0.062 in 1H 2020)

Revenue beats expectations

Integral Diagnostics Limited Announces Retirement of Dr. Chien Ho as Executive Director, Effective on March 1, 2021

Integral Diagnostics Limited to Report First Half, 2021 Results on Feb 22, 2021

New 90-day high: AU$4.48

New 90-day high: AU$4.42

Executive Director recently sold AU$266k worth of stock

Executive Director recently sold AU$123k worth of stock

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Ascot Radiology Limited for NZD 54 million.

Integral Diagnostics Limited (ASX:IDX) completed the acquisition of Ascot Radiology Limited.

New 90-day high - AU$4.30

Earnings released

Desglose de ingresos y gastos

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado